Serum CGRP in migraine patients using erenumab as preventive treatment

ConclusionLower serum CGRP-LI 2 –4 weeks after starting treatment with erenumab was associated with a higher reduction in migraine days after three months of treatment. Although the underlying mechanisms remain to be determined, this suggests that changes in CGRP levels, shortly after starting erenumab, are important for its cli nical effect.
Source: The Journal of Headache and Pain - Category: Neurology Source Type: research